Lyell Immunopharma, Inc. (LYEL) Fair Value 2026

LYEL · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-28, Lyell Immunopharma, Inc. (LYEL) trades at $14.53. QOC: 4.8/10. Value Trap Risk: 63/100 (DANGER). 0/13 models active.

Key Facts

Ticker
LYEL
Price
$14.53
Quality Score
4.8/10
Value Trap Risk
63/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give LYEL?

0 Intrinsic Value Models vs. Current Price ($14.53)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Lyell Immunopharma, Inc. (LYEL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lyell Immunopharma, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About LYEL?

0 of 13 models are currently active for LYEL. See which stocks rank higher →

How Does LYEL Rank in Biotechnology?

Among 625 Biotechnology stocks, LYEL ranks #377 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Lyell Immunopharma, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is LYEL a Value Trap?

CirclFi's Value Trap algorithm assigns LYEL a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Lyell Immunopharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Lyell Immunopharma, Inc. earns a quality score of 4.8/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LYEL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lyell Immunopharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

QNCXQuince Therapeutics, Inc.QOC 4.8MLYSMineralys Therapeutics, Inc.QOC 4.8TTRXTurn Therapeutics Inc.QOC 4.8ATOSAtossa Therapeutics, Inc.QOC 4.8CNSYCerenome, Inc.QOC 4.8LONALeonaBio, Inc.QOC 4.8VBIOValion Bio, Inc.QOC 4.0OCULOcular Therapeutix, Inc.QOC 6.8CNTBConnect Biopharma Holdings LimitedQOC 5.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: QNCX · MLYS · TTRX · ATOS · CNSY · LONA · VBIO · OCUL · CNTB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LYEL?

6 companies across all industries closest to LYEL’s Quality of Company score of 4.8/10.

FLYEFly-E Group, Inc.QOC 4.8POLAPolar Power, Inc.QOC 4.8DFSCDEFSEC Technologies Inc.QOC 4.8OPTTOcean Power Technologies, Inc.QOC 4.8ALURAllurion Technologies Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FLYE · POLA · DFSC · OPTT · ALUR · NVDA

Where Does LYEL Sit in CirclFi's Biotechnology Rankings?

LYEL is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Lyell Immunopharma, Inc.’s Valuation?

What is Lyell Immunopharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Lyell Immunopharma, Inc. (LYEL). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LYEL overvalued or undervalued right now?

At $14.53, 0 of 0 active models suggest LYEL may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Lyell Immunopharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for LYEL?

Lyell Immunopharma, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on LYEL?

CirclFi analyzes LYEL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is LYEL a value trap in 2026?

Lyell Immunopharma, Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Lyell Immunopharma, Inc. (LYEL) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/LYEL/ · Methodology
Primary sources for this LYEL valuation
  • Financial statements: Lyell Immunopharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001806952) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LYEL as of ; valuations recomputed .